MARLBOROUGH, Mass.,
Sept. 15, 2015 /PRNewswire/
-- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a
biotechnology company focused on discovering and developing
innovative therapies primarily in the areas of dermatology and
ophthalmology, today announced that Dr. Geert Cauwenbergh, RXi's President and CEO, will
be participating in the upcoming 15th Annual Biotech in Europe
Forum for Global Partnering and Investment Conference, with an oral
presentation and panel discussion. This Forum is recognized as the
leading international stage for those interested in investing and
partnering in the biotech and life sciences industry.
Logo -
http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
On Tuesday, September 29, 2015
from 12:00 to 1:00 p.m. CEST, Dr.
Cauwenbergh will discuss the development and partnering strategy
for RXi's proprietary self-delivering RNAi (sd-rxRNA®)
platform during a panel discussion entitled Platform
Technologies & Novel Therapeutics.
In addition, on that same day at 3:15
p.m. CEST, Dr. Cauwenbergh will present a corporate overview
that includes multiple business development opportunities available
based on RXi's proprietary sd-rxRNA® platform and
extensive intellectual property portfolio. The presentation
will be available on the Company's website at www.rxipharma.com
approximately one hour after the presentation.
About the 15th Annual Biotech in Europe
Forum
The Forum draws together an exciting cross-section of
early-stage/pre-IPO, late-stage and public companies with leading
investors, analysts, money managers and pharma licensing
executives. This meeting is being held September 29-30, 2015 at the Congress Center in
Basel, Switzerland.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
biotechnology company focused on discovering and developing
innovative therapeutics primarily in the areas of dermatology and
ophthalmology that address high-unmet medical needs. Our discovery
and clinical development programs are based on siRNA technology as
well as immunotherapy agents. These compounds include, but are not
limited to, our proprietary, self-delivering RNAi
(sd-rxRNA®) compounds for the treatment of dermal and
ocular scarring. It also includes an immunomodulator,
Samcyprone™, a proprietary topical formulation of
diphenylcyclopropenone (DPCP), for the treatment of disorders such
as alopecia areata, warts, non-malignant skin tumors and cutaneous
metastases of melanoma.
RXi's novel, self-delivering RNAi (sd-rxRNA®)
compounds are designed for therapeutic use and have drug-like
properties, such as high potency, target specificity, serum
stability, reduced immune response activation, and efficient
cellular uptake. sd-rxRNAs have been shown, in vitro and in vivo,
to achieve efficient spontaneous cellular uptake and potent,
long-lasting intracellular activity.
RXI-109, an sd-rxRNA compound, is the Company's first clinical
development candidate. RXI-109 silences Connective Tissue Growth
Factor (CTGF), which plays a key role in tissue regeneration and
repair and is initially being developed to reduce or inhibit scar
formation in the skin and in the eye. RXI-109 is currently
being evaluated in Phase 2a clinical trials in dermatology and a
Phase 1/2 trial is planned to initiate this year in ophthalmology.
The Company's sd-rxRNA technology platform is broadly protected by
multiple issued patents and numerous patent applications.
RXi's robust pipeline, coupled with an extensive patent
portfolio, provides for product and business development
opportunities across a broad spectrum of therapeutic areas. We are
committed to being a partner of choice for academia, small
companies, and large multinationals. We welcome ideas and proposals
for strategic alliances, including in- and out-licensing
opportunities, to advance and further develop strategic areas of
interest. Additional information may be found on the Company's
website, www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about: our ability to successfully develop RXI-109,
Samcyprone™ and our other product candidates
(collectively "our product candidates"); the future success of our
clinical trials with our product candidates; the timing for the
commencement and completion of clinical trials; our ability to
enter into strategic partnerships and the future success of these
strategic partnerships; and our ability to deploy our
sd-rxRNA® technology through partnerships, as well as
the prospects of these partnerships to provide positive returns.
Forward-looking statements about expectations and development plans
of RXi's product candidates and partnerships involve significant
risks and uncertainties, including the following: risks that we may
not be able to successfully develop and commercialize our product
candidates; risks that product development and clinical studies may
be delayed, not proceed as planned and/or be subject to significant
cost over-runs; risks related to the development and
commercialization of products by competitors; risks related to our
ability to control the timing and terms of collaborations with
third parties; and risks that other companies or organizations may
assert patent rights preventing us from developing or
commercializing our product candidates. Additional risks are
detailed in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q under the caption "Risk
Factors." Readers are urged to review these risk factors and
to not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-present-at-the-15th-annual-biotech-in-europe-forum-for-global-partnering-and-investment-conference-300142798.html
SOURCE RXi Pharmaceuticals Corporation